

- Rizzo M, Malizia R, Maggio A, Fabiano C, Barbaria F, Craxi A: Long-term efficacy of α -interferon in β -thalassemics with chronic hepatitis C. *Blood* 1997; 90: 2207–2212
37. Hayashi H, Takikawa T, Nishimura N, Yano M: Serum aminotransferase levels as an indicator of the effectiveness of venesection for chronic hepatitis C. *J Hepatol* 1995; 22: 268–271
 38. Bacon BR, Rebholz AE, Fried M, Di Bisceglie AM: Beneficial effect of iron reduction therapy in patients with chronic hepatitis C, who failed to respond to interferon- α . *Hepatology* 1993; 18: 150A
 39. Piperno A, Sampietro M, D'Alba R, Roffi L, Fargion S, Parma S, Nicoli C, Corbetta N, Pozzi M, Arosio V, Boari G, Fiorelli G: Iron stores, response to α -interferon therapy, and effects of iron depletion in chronic hepatitis C. *Liver* 1996; 16: 248–254
 40. Clemente MG, Congia M, Lai ME, Lilliu F, Lampis R, Frau F, Frau MR, Faa G, Diana G, Dessi C, *et al.*: Effect of iron overload on the response to recombinant interferon- α treatment in transfusion-dependent patients with thalassemia major and chronic hepatitis C. *J Pediatr* 1994; 125: 123–128
 41. Beinker NK, Voigt MD, Arendse M, Smit J, Stander IA, Kirsch RE: Threshold effect of liver iron content on hepatic inflammation and fibrosis in hepatitis B and C. *J Hepatol* 1996; 25: 633–638
 42. Kaji K, Nakanuma Y, Sasaki M, Unoura M, Kobayashi K, Nonomura A: Hemosiderin deposition in portal endothelial cells: a novel hepatic hemosiderosis frequent in chronic viral hepatitis B and C. *Hum Pathol* 1995; 26: 1080–1085
 43. Fong TL, Han SH, Tsai NC, Morgan TR, Mizokami M, Qian D, Phan C, Goad K, Redeker AG: A pilot randomized, controlled trial of the effect of iron depletion on long-term response to α -interferon in patients with chronic hepatitis C. *J Hepatol* 1998; 28: 369–374
 44. Kaserer K, Fiedler R, Steindl P, Muller CH, Wrba F, Ferenci P: Liver biopsy is a useful predictor of response to interferon therapy in chronic hepatitis C. *Histopathology* 1998; 32: 454–461
 45. D'Alba R, Sampietro M, Fargion S, Roffi L, Parma S, Pozzi M, Nicoli C, Corbetta N, Arosio V, Piperno A: Iron stores and virus genotypes in chronic hepatitis C: relation with α -interferon response. *Hepatology* 1995; 22: 180A
 46. Bacon BR, Powell LW, Adams PC, Kresina TF, Hoofnagle JH: Molecular medicine and hemochromatosis: at the crossroads. *Gastroenterology* 1999; 116: 193–207
 47. Stuart KA, Busfield F, Jazwinska EC, Gibson P, Butterworth LA, Cooksley WG, Powell LW, Crawford DH: The C282Y mutation in the haemochromatosis gene (HFE) and hepatitis C virus infection are independent cofactors of porphyria cutanea tarda in Australian patients. *J Hepatol* 1998; 28: 404–409
 48. Barrett S, Callagy G, Ryan E, O'Keane JC, Mathuna PM, Crowe J: The C282Y mutation is not a significant cofactor for more severe liver disease in a cohort of Irish hepatitis C patients. *Gastroenterology* 1988; 114: A1209
 49. Bacon BR, Olynyk JK, Brunt EM, Britton RS, Wolff RK: HFE genotype in patients with hemochromatosis and other liver disease. *Ann Int Med* 1999; 130: 953–962
 50. Smith BC, Gorve J, Guzail MA, Day CP, Daly AK, Burt AD, Bassendine MF: Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. *Hepatology* 1998; 27: 1695–1699
 51. Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, Obando J, Di Bisceglie A, Tattrie C, Tortorelli K, LeClair P, Mercurio MG, Lambrecht RW: Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. *Hepatology* 1998; 27: 1661–1669
 52. Roberts AG, Whatley SD, Morgan RR, Worwood M, Elder GH: Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. *Lancet* 1997; 349: 321–323
 53. Stal P, Hulterantz R: Iron increases ethanol toxicity in rat liver. *J Hepatol* 1993; 17: 108–115
 54. Olynyk J, Hall P, Reed W, Williams P, Kerr R, Mackinnon M: A long-term study of the interaction between iron and alcohol in an animal model of iron overload. *J Hepatol* 1995; 22: 671–676
 55. Mackinnon M, Clayton C, Plummer J, Ahern M, Cmielewski P, Ilsley A, Hall P: Iron overload facilitates hepatic fibrosis in the rat alcohol/low-dose carbon tetrachloride model. *Hepatology* 1995; 21: 1083–1088
 56. Higuera V, Raya A, Rodrigo JM, Serra MA, Roma J, Romero FJ: Interferon decreases serum lipid peroxidation products of hepatitis C patients. *Free Radic Biol Med* 1994; 16: 131–133
 57. Farinati F, Cardin R, De Maria N, Della Libera G, Marafin C, Lecis E, Burra P, Floreani A, Cecchetto A, Naccarato R: Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. *J Hepatol* 1995; 22: 449–456
 58. Kikuyama M, Kobayashi Y, Kawasaki T, Yoshimi T: Hepatic lipid peroxidation in chronic hepatitis C. *Hepatology* 1995; 22: 276A
 59. Maher JJ, Zia S, Tzagarakis C: Acetaldehyde-induced stimulation of collagen synthesis and gene expression is dependent on conditions of cell culture: studies with rat lipocytes and fibroblasts. *Alcohol Clin Exp Res* 1994; 18: 403–409
 60. Maher JJ, Tzagarakis C, Gimenez A: Malondialdehyde stimulates collagen production by hepatic lipocytes only upon activation in primary culture. *Alcohol* 1994; 29: 605–610
 61. Leonarduzzi G, Scavazza A, Biasi F, Chiarpotto E, Camandola S, Vogel S, Dargel R, Poli G: The lipid peroxidation end product 4-hydroxy-2,3-nonenal up-regulates transforming growth factor β_1 expression in the macrophage lineage: a link between oxidative injury and fibrosclerosis. *FASEB J* 1997; 11: 851–857
 62. Parola M, Muraca R, Dianzani I, Barrera G, Leonarduzzi G, Bendinelli P, Piccoletti R, Poli G: Vitamin E dietary supplementation inhibits transforming growth factor β_1 gene expression in the rat liver. *FEBS Lett* 1992; 308: 267–270
 63. Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D: Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. *Hepatology* 1997; 26: 485–490
 64. Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, Kumada H, Kawanishi M: A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. *Hepatology* 1993; 18: 47–53
 65. Kew MC: Hepatic tumors and cysts. In: Feldman M, Scharschmidt BF, Sleisenger MH, eds, *Sleisenger and Fordtran's Gastrointestinal and Liver Diseases: Pathophysiology/diagnosis/management*. 6th Ed, Philadelphia, W B Saunders Co, 1998; 1364–1387
 66. Sell S, Dunsford HA: Evidence for the stem cell origin of hepatocellular carcinoma and cholangiocarcinoma. *Am J Pathol* 1989; 134: 1347–1363
 67. Lemire JM, Shiojiri N, Fausto N: Oval cell proliferation and the origin of small hepatocytes in liver injury induced by D-galactosamine. *Am J Pathol* 1991; 139: 535–552
 68. Evarts RP, Nagy P, Marsden E, Thorgeirsson SS: A precursor-product relationship exists between oval cells and hepatocytes in rat liver. *Carcinogenesis* 1987; 8: 1737–1740
 69. Hixson DC, Fowler LC: Development and phenotypic heterogeneity of intrahepatic biliary epithelial cells. In: Sirica AE, Longnecker DS, eds, *Biliary and Pancreatic Ductal Epithelia: Pathobiology and Pathophysiology*. New York, Marcel Dekker,